PrimeRFP SCOUT · Federal Contract Recompete Brief

75N93022C00059AMR development epetraborole NOVEL therapeutic — An2 Therapeutics, Inc

An2 Therapeutics, Inc holds $4.3M across 1 federal awards, concentrated at Department of Health and Human Services (HHS). Competition previously drew 30 offers. Set-aside status: NONE. Recompete timing centers on the Sep 30, 2026 PoP end — agencies typically plan 12–18 months ahead.

National Institutes Of Health Niaid

Awarding office

An2 Therapeutics, Inc

Recipient

Sep 30, 2026

PoP end

$9.2M

Obligated

$18.3M

Potential

541715

NAICS

AN12

PSC

NONE

Set-aside

30 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs An2 Therapeutics, Inc — $90

Contract facts

NONE

Contract number75N93022C00059

AgencyNational Institutes Of Health Niaid

Awarding officeNational Institutes Of Health Niaid

Awarding agencyDepartment of Health and Human Services (HHS)

Funding agencyDepartment of Health and Human Services (HHS)

IncumbentAn2 Therapeutics, Inc

CAGE822Z2

UEIDD4FE2GE4L78

NAICS541715

PSCAN12

Place of performanceMENLO PARK CA

Pricing typeCost No Fee

Extent competedFull And Open Competition

Related solicitationPHS-2021-1

PoP startSep 20, 2022

PoP end (current)Sep 30, 2026

Obligated$9.2M

Current value$9.2M

Potential value$18.3M

DEVELOPMENT OF EPETRABOROLE AS A NOVEL THERAPEUTIC FOR MELIOIDOSIS AND ADDITIONAL ANTIMICROBIAL RESISTANT (AMR) BACTERIAL BIOTHREAT PATHOGENS. is a federal NONE award for National Institutes Of Health Niaid held by An2 Therapeutics, Inc. Estimated value $18.3M ($9.2M obligated). Current period of performance ends Sep 30, 2026. Last award drew 30 bidders. Place of performance: MENLO PARK CA. Related solicitation PHS-2021-1.

DEVELOPMENT OF EPETRABOROLE AS A NOVEL THERAPEUTIC FOR MELIOIDOSIS AND ADDITIONAL ANTIMICROBIAL RESISTANT (AMR) BACTERIAL BIOTHREAT PATHOGENS.

Recompete timing

Public

● Expiring in 23 days

Current PoP ends Sep 30, 2026 (23 days remaining). Agencies typically plan 12–18 months ahead — at 0.8 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

An2 Therapeutics, Inc — $4.3M obligated across 1 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$4.3M · 100% of firm total

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75N93022C00059?

75N93022C00059 (AMR development epetraborole NOVEL therapeutic) is a National Institutes Of Health Niaid award with a potential value of $18.3M, currently held by An2 Therapeutics, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75N93022C00059?

National Institutes Of Health Niaid awarded 75N93022C00059 to An2 Therapeutics, Inc (potential $18.3M).

Who is the incumbent on 75N93022C00059?

An2 Therapeutics, Inc is the incumbent with $4.3M across 1 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2026.

When does An2 Therapeutics, Inc’s 75N93022C00059 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 30, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on 75N93022C00059 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Apr 24, 2026